Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zevra TherapeuticsZVRA -2.10%69 Quick Ratio is 5.12 as of Jun. 2026, which is 3% above its 10-year median of 4.98. GuruFocus rates ZVRA with a GF Score™ of 69/100 and a GF Value™ of $20.92 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,409 Biotechnology companies, Zevra Therapeutics ranks better than 61.04% on this metric.
Zevra Therapeutics (NAS:ZVRA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Zevra Therapeutics Quick Ratio Related Terms
Zevra Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Zevra Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zevra Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zevra Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Zevra Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Zevra Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zevra Therapeutics (ZVRA) has a Quick Ratio of 5.12 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Zevra Therapeutics and its competitors. This is near median its historical median of 4.98. Over the past decade, Zevra Therapeutics' Quick Ratio has ranged from 0.07 to 36.41. According to the industry distribution chart, Zevra Therapeutics ranks #549 out of 1409 companies in the Biotechnology industry, placing it in the top 39%.
Is Zevra Therapeutics' Quick Ratio too high?
Zevra Therapeutics' current Quick Ratio of 5.12 is near median its 10-year median of 4.98. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 36.41. The Biotechnology industry median Quick Ratio is 3.52. Zevra Therapeutics' value of 5.12 is 45.5% above this industry median. Based on the distribution chart, Zevra Therapeutics ranks #549 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zevra Therapeutics has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zevra Therapeutics' Quick Ratio compare to TECX and RLMD?
According to the Biotechnology industry distribution chart, Zevra Therapeutics ranks #549 out of 1409 companies for Quick Ratio. This puts Zevra Therapeutics in the upper half of its industry. The industry median Quick Ratio is 3.52. Zevra Therapeutics' value of 5.12 is 45.5% above this benchmark. Historically, Zevra Therapeutics' own Quick Ratio has ranged from 0.07 to 36.41 over the past decade. While the company's 10-year median is 4.98 vs. the industry median of 3.52, Zevra Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.52, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zevra Therapeutics's current Quick Ratio of 5.12 is 45.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Zevra Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zevra Therapeutics's current Quick Ratio is 5.12, which is near median its own 10-year median of 4.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zevra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zevra Therapeutics (ZVRA) is currently considered Possible Value Trap. The stock's GF Value™ is $20.92, compared to a current price of $11.20 — trading 46.5% below its estimated fair value. The current Quick Ratio is 5.12, which is near median its 10-year median of 4.98 and 45.5% above the Biotechnology industry median of 3.52. Zevra Therapeutics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Zevra Therapeutics (ZVRA), the current Quick Ratio is 5.12 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zevra Therapeutics (ZVRA) Overvalued in 2026?
Based on GuruFocus' analysis, Zevra Therapeutics stock appears to be undervalued.
The current stock price of $11.20 is trading 46.5% below its estimated GF Value™ of $20.92.
GuruFocus considers Zevra Therapeutics to be Possible Value Trap.
Key valuation signals for ZVRA:
Quick Ratio: 5.12 (near median its 10-year median of 4.98)
GF Value™: $20.92 vs. price of $11.20 (46.5% below fair value)
Industry Position: 45.5% above the Biotechnology median (#549 of 1409)
No single metric tells the full story. See the ZVRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
69GF Score
Get the complete analysis for ZVRA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZVRA has been successfully added to your 
